ZECCHINI EDWARD J sold $508K of CYRX

ZECCHINI EDWARD J (Chief Digital and Tech Officer) sold 35,000 shares of Cryoport, Inc. (CYRX) at an average of $14.50 ($14.47–$15.23, $0.51M total) across 2 trades over 2026-06-10 to 2026-06-11.

Original reporting
SEC EDGAR · ZECCHINI EDWARD J
Published Jun 12, 2026, 10:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 10:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CYRX
Bearish
medium confidence
Mentioned
$CYRX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYRXBearishLow
01

Why it matters

The only new information is the officer’s sale size, timing, and price range; it may slightly affect sentiment but does not change fundamentals on its own.

02

Market read

Traders may factor the insider sale into short-term sentiment, but the lack of accompanying operational news limits tradable edge.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, which can increase interpretive uncertainty; traders should check for other recent insider activity and any concurrent company disclosures.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed today (2026-06-12) covering sales on 2026-06-10 to 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for Cryoport, Inc. (CYRX).

Company-level read

Ticker impact

$CYRXBearishMedium confidence
Context

Cryoport officer sold 35,000 shares in open-market transactions totaling about $507,563, per a fresh SEC Form 4 filing.

Expected impact

Likely limited near-term impact; any effect should be small unless paired with other negative company-specific catalysts.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not disclose new business developments—only an open-market sale with no stated 10b5-1 plan.

Market effects

No clear sector read-through; this is a single-company insider transaction without additional operational/regulatory information.

None indicated.

None indicated.

Counterpoint

Open-market insider sales can be routine liquidity/portfolio rebalancing and may not reflect negative expectations, especially without any accompanying negative company news.

Key entities

  • Cryoport, Inc.

    Company whose insider transaction is disclosed on SEC Form 4.

  • Zecchini Edward J

    Chief Digital and Tech Officer who sold 35,000 shares in two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CYRXMed

CryoPort Q3 Earnings Call Highlights

CryoPort reported Q3 supporting 23 commercial therapies and 788 clinical trials. China operations contribute 3-4% of revenue. The company expects five regulatory filings and two potential new therapy approvals in 2026. Guidance is conservative, focusing on existing clients. Expansion plans include new BioServices capabilities in Paris and California, with long-term margin goals of 55% gross and 30% adjusted EBITDA.

$CYRXMed

Cryoport Reports Third Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Third Quarter 2026 Financial Results · Third quarter revenue grew 14% year-over-year to $50.2 million · Commercial Cell and Gene Therapy revenue increased 20% year-over-year · Supporting a record 788 global clinical trials and 23 commercially approve

$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

$CYRXMed

Cryoport Reports Second Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin